11. Eye - guidance

To access BNF Formulary section click on the link under BNF Section/s

To access the Guidance Document click on the highlighted text under the Title column

Use documents past their review date with Caution

BNF Section/s	Title	Issuing Body	Date of Issue	Update Due
11.6	Brolucizumab	High-Cost Drugs
11.6	Brolucizumab for treating diabetic macular oedema TA820	NICE	Aug 2022
11.6	Dexamethasone intravitreal implant (Ozurdex)	High-Cost Drugs
11.6	Dexamethasone intravitreal implant for treating diabetic macular oedema TA824	NICE	Sep 2022
11.2	Dry Eyes - Kent and Medway Dry Eye Guidance	Kent and Medway ICB	Feb 2024	Feb 2026
11.6	Ranibizumab Biosimilar (Ongavir)	High-Cost Drugs
11.6	Ranibizumab and pegaptanib for the treatment of age-related macular degeneration TA155	NICE	May 2012
11.6	Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion TA283	NICE	May 2013
11.6	Ranibizumab for treating diabetic macular oedema TA274	NICE	Feb 2013
11.6	Ranibizumab for treating choroidal neovascularisation associated with pathological myopia TA298	NICE	Nov 2013
11.6	Faricimab	High-Cost Drugs
11.6	Faricimab for treating diabetic macular oedema TA799	NICE	Jun 2022
11.6	Faricimab for treating wet age-related macular degeneration TA800	NICE	Jun 2022